JP2017214418A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017214418A5 JP2017214418A5 JP2017157337A JP2017157337A JP2017214418A5 JP 2017214418 A5 JP2017214418 A5 JP 2017214418A5 JP 2017157337 A JP2017157337 A JP 2017157337A JP 2017157337 A JP2017157337 A JP 2017157337A JP 2017214418 A5 JP2017214418 A5 JP 2017214418A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- aryl
- divalent
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000000565 sulfonamide group Chemical group 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005599 alkyl carboxylate group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361773778P | 2013-03-06 | 2013-03-06 | |
| US61/773,778 | 2013-03-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561540A Division JP6196328B2 (ja) | 2013-03-06 | 2014-03-04 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019043933A Division JP6672499B2 (ja) | 2013-03-06 | 2019-03-11 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017214418A JP2017214418A (ja) | 2017-12-07 |
| JP2017214418A5 true JP2017214418A5 (enExample) | 2019-01-31 |
| JP6496788B2 JP6496788B2 (ja) | 2019-04-03 |
Family
ID=50389505
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561540A Expired - Fee Related JP6196328B2 (ja) | 2013-03-06 | 2014-03-04 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
| JP2017157337A Expired - Fee Related JP6496788B2 (ja) | 2013-03-06 | 2017-08-17 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
| JP2017157336A Expired - Fee Related JP6496787B2 (ja) | 2013-03-06 | 2017-08-17 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
| JP2019043933A Expired - Fee Related JP6672499B2 (ja) | 2013-03-06 | 2019-03-11 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561540A Expired - Fee Related JP6196328B2 (ja) | 2013-03-06 | 2014-03-04 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017157336A Expired - Fee Related JP6496787B2 (ja) | 2013-03-06 | 2017-08-17 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
| JP2019043933A Expired - Fee Related JP6672499B2 (ja) | 2013-03-06 | 2019-03-11 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20140256685A1 (enExample) |
| EP (1) | EP2964214A1 (enExample) |
| JP (4) | JP6196328B2 (enExample) |
| KR (2) | KR20210024691A (enExample) |
| CN (2) | CN105007908B (enExample) |
| AR (1) | AR095035A1 (enExample) |
| AU (3) | AU2014226001B2 (enExample) |
| BR (2) | BR122017004256A2 (enExample) |
| CA (3) | CA2899804A1 (enExample) |
| HK (2) | HK1219661A1 (enExample) |
| RU (1) | RU2696487C2 (enExample) |
| TW (1) | TW201446241A (enExample) |
| WO (1) | WO2014138046A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5982001B2 (ja) * | 2011-10-26 | 2016-08-31 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ホルミルペプチド受容体様１（ｆｐｒｌ−１）受容体モジュレーターとしてのｎ−尿素置換アミノ酸のアミド誘導体 |
| NZ700733A (en) * | 2012-04-16 | 2016-07-29 | Allergan Inc | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
| MA37618B1 (fr) | 2012-05-16 | 2017-08-31 | Actelion Pharmaceuticals Ltd | Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx |
| WO2013171687A1 (en) | 2012-05-16 | 2013-11-21 | Actelion Pharmaceuticals Ltd | 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
| CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
| WO2014138046A1 (en) * | 2013-03-06 | 2014-09-12 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases |
| AR096686A1 (es) | 2013-06-25 | 2016-01-27 | Actelion Pharmaceuticals Ltd | Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx |
| WO2015009545A1 (en) * | 2013-07-16 | 2015-01-22 | Allergan, Inc. | Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators |
| TW201536289A (zh) | 2013-07-18 | 2015-10-01 | Actelion Pharmaceuticals Ltd | 作為ａｌｘ受體激動劑之經哌取代橋聯螺［２，４］庚烷衍生物 |
| AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
| WO2015116566A1 (en) * | 2014-01-29 | 2015-08-06 | Allergan, Inc. | 2,5-dioxoimidazolidin-1-yl-3-urea derivatives as formyl peptide modulators |
| US9663457B2 (en) | 2014-04-09 | 2017-05-30 | Allergan, Inc. | Carbamoyl hydrazine derivatives as formyl peptide modulators |
| BR112016027133A8 (pt) | 2014-05-21 | 2021-06-29 | Allergan Inc | derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso |
| EA034227B1 (ru) * | 2015-12-10 | 2020-01-20 | Бристол-Майерс Сквибб Компани | Пиперидиноновые агонисты формилпептидного рецептора 2 и формилпептидного рецептора 1 |
| CN109715602A (zh) * | 2016-03-28 | 2019-05-03 | 阿勒根公司 | 苯基脲衍生物作为n-甲酰肽受体调节剂 |
| EP3442950A1 (en) * | 2016-04-12 | 2019-02-20 | Allergan, Inc. | Phenyl urea derivatives as n-formyl peptide receptor modulators |
| RU2768587C2 (ru) * | 2016-10-06 | 2022-03-24 | Дайити Санкио Компани, Лимитед | Производное мочевины |
| GB2561540A (en) * | 2017-03-13 | 2018-10-24 | Nodthera Ltd | Chemical compounds |
| ES2799098B2 (es) * | 2019-06-10 | 2021-12-10 | Univ Madrid Carlos Iii | Aptameros agonistas del receptor fpr2 y usos de los mismos |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4521210A (en) | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
| JPS63232846A (ja) | 1987-03-20 | 1988-09-28 | Haruo Ogura | 新規な固定相担体 |
| WO2001014328A2 (en) * | 1999-08-20 | 2001-03-01 | Merck & Co., Inc. | Substituted ureas as cell adhesion inhibitors |
| DE10005275A1 (de) * | 2000-02-07 | 2001-08-09 | Bayer Ag | Neuartige Glycokonjugate |
| EP1162194A1 (en) | 2000-06-06 | 2001-12-12 | Aventis Pharma Deutschland GmbH | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use |
| DE10063008A1 (de) | 2000-12-16 | 2002-06-20 | Merck Patent Gmbh | Carbonsäureamidderivate |
| EP1537075B1 (en) * | 2002-09-05 | 2009-07-01 | Neurosearch A/S | Diarylurea derivatives and their use as chloride channel blockers |
| US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| EP1695961A4 (en) | 2003-12-17 | 2007-10-24 | Takeda Pharmaceutical | UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE |
| WO2006065755A2 (en) | 2004-12-13 | 2006-06-22 | Glaxo Group Limited | Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists |
| WO2007076055A2 (en) * | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| KR20090121832A (ko) * | 2008-05-23 | 2009-11-26 | 인제대학교 산학협력단 | 2-(2-히드록시벤조일)히드라진카르복시아미드 유도체 또는이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를유효 성분으로 함유하는 선택적 면역 억제용 약학적 조성물 |
| CN102209701B (zh) * | 2008-11-11 | 2014-10-15 | 西格纳姆生物科学公司 | 异戊二烯基化合物和其方法 |
| KR20100101055A (ko) * | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동 관련 질환의 치료 또는 예방용 약학적 조성물 |
| WO2011073918A2 (en) * | 2009-12-16 | 2011-06-23 | Actelion Pharmaceuticals Ltd | Peptides as modulators of fprl1 and/or fprl2 |
| CA2803920A1 (en) * | 2010-06-24 | 2011-12-29 | Richard Beard | Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
| CA2819457A1 (en) * | 2010-12-03 | 2012-06-07 | Allergan, Inc. | Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
| CA2827005A1 (en) | 2011-02-11 | 2012-08-16 | Allergan, Inc. | Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators |
| US8653299B2 (en) | 2011-03-17 | 2014-02-18 | Allergan, Inc. | Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| CA2839735A1 (en) | 2011-06-17 | 2012-12-20 | Yong-xin LI | D-serine for the treatment of visual system disorders |
| US8440684B2 (en) | 2011-07-11 | 2013-05-14 | Allergan, Inc. | Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| JP5982001B2 (ja) * | 2011-10-26 | 2016-08-31 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ホルミルペプチド受容体様１（ｆｐｒｌ−１）受容体モジュレーターとしてのｎ−尿素置換アミノ酸のアミド誘導体 |
| US8492556B2 (en) * | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| US8541577B2 (en) * | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
| EP2814815A1 (en) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Imidazolidine-2,4-dione derivatives as n-formyl peptide receptor 2 modulators |
| NZ700733A (en) * | 2012-04-16 | 2016-07-29 | Allergan Inc | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
| CA2898301C (en) * | 2013-03-06 | 2021-11-16 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases |
| WO2014138046A1 (en) * | 2013-03-06 | 2014-09-12 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases |
| WO2015009545A1 (en) * | 2013-07-16 | 2015-01-22 | Allergan, Inc. | Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators |
| US20150080466A1 (en) | 2013-09-19 | 2015-03-19 | Allergan, Inc. | Diphenyl urea derivatives as formyl peptide receptor modulators |
| JP6496728B2 (ja) | 2013-11-21 | 2019-04-03 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ホルミルペプチド受容体の調節因子としてのカルバミン酸フェニル誘導体 |
| BR112016027133A8 (pt) * | 2014-05-21 | 2021-06-29 | Allergan Inc | derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso |
-
2014
- 2014-03-04 WO PCT/US2014/020273 patent/WO2014138046A1/en not_active Ceased
- 2014-03-04 CA CA2899804A patent/CA2899804A1/en not_active Abandoned
- 2014-03-04 KR KR1020217005968A patent/KR20210024691A/ko not_active Ceased
- 2014-03-04 BR BR122017004256A patent/BR122017004256A2/pt not_active Application Discontinuation
- 2014-03-04 EP EP14713302.9A patent/EP2964214A1/en not_active Withdrawn
- 2014-03-04 AU AU2014226001A patent/AU2014226001B2/en not_active Ceased
- 2014-03-04 RU RU2015134778A patent/RU2696487C2/ru active
- 2014-03-04 HK HK16107753.4A patent/HK1219661A1/zh unknown
- 2014-03-04 US US14/196,155 patent/US20140256685A1/en not_active Abandoned
- 2014-03-04 CA CA3114477A patent/CA3114477A1/en not_active Abandoned
- 2014-03-04 CN CN201480011861.8A patent/CN105007908B/zh not_active Expired - Fee Related
- 2014-03-04 CN CN201711029910.2A patent/CN107714683A/zh active Pending
- 2014-03-04 BR BR112015021392-8A patent/BR112015021392B1/pt not_active IP Right Cessation
- 2014-03-04 KR KR1020157024039A patent/KR102223384B1/ko not_active Expired - Fee Related
- 2014-03-04 JP JP2015561540A patent/JP6196328B2/ja not_active Expired - Fee Related
- 2014-03-04 CA CA3114347A patent/CA3114347A1/en not_active Abandoned
- 2014-03-06 AR ARP140100733A patent/AR095035A1/es unknown
- 2014-03-06 TW TW103107759A patent/TW201446241A/zh unknown
-
2017
- 2017-04-18 US US15/490,127 patent/US10434112B2/en not_active Expired - Fee Related
- 2017-08-17 JP JP2017157337A patent/JP6496788B2/ja not_active Expired - Fee Related
- 2017-08-17 JP JP2017157336A patent/JP6496787B2/ja not_active Expired - Fee Related
-
2018
- 2018-08-22 HK HK18110777.8A patent/HK1251185A1/zh unknown
-
2019
- 2019-03-06 AU AU2019201538A patent/AU2019201538B2/en not_active Ceased
- 2019-03-11 JP JP2019043933A patent/JP6672499B2/ja not_active Expired - Fee Related
- 2019-09-10 US US16/566,682 patent/US10799518B2/en not_active Expired - Fee Related
-
2020
- 2020-09-22 US US17/028,440 patent/US20210008085A1/en not_active Abandoned
- 2020-09-22 US US17/028,416 patent/US20210000846A1/en not_active Abandoned
-
2021
- 2021-05-18 AU AU2021203183A patent/AU2021203183A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017214418A5 (enExample) | ||
| JP2017214417A5 (enExample) | ||
| JP2017066164A5 (enExample) | ||
| JP2018009012A5 (enExample) | ||
| JP2017214416A5 (enExample) | ||
| BR112015005331B8 (pt) | Eletrólito de polímero em gel e dispositivo eletroquímico incluindo o mesmo | |
| MX385158B (es) | Derivados indol para uso en medicina. | |
| NZ734896A (en) | Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same | |
| JP2015527363A5 (enExample) | ||
| CY1120477T1 (el) | Ενεργοποιητης του υποδοχεα που ενεργοποιειται απο πολλαπλασιαστες των υπεροξεισωματων | |
| AR091858A1 (es) | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) | |
| AR108245A1 (es) | Síntesis de indazoles | |
| CO6180506A2 (es) | Inhibidores de la proteasa ns3 del hcv | |
| ES2570177T3 (es) | Compuesto heterocíclico | |
| RU2011135977A (ru) | Производное n-ацилантраниловой кислоты или его соль | |
| BR112012033690A2 (pt) | sais de cálcio de compostos como agentes anti-inflamatórios, imunomodulares e antitroliferativos | |
| WO2008126804A1 (ja) | レジスト下層膜形成組成物 | |
| CO6270232A2 (es) | Derivados de catecolamina utiles para el tratamiento de enfermedades de parkinson | |
| DE602007008389D1 (de) | Synthese von phenolischen estern von hydroxymethylphenolen | |
| EA201270359A1 (ru) | Терапевтическое средство от расстройств настроения | |
| JP2019500319A5 (enExample) | ||
| MA39205B1 (fr) | Polymères contenant des amines primaires utiles en tant qu'inhibiteurs de tartre | |
| UY32246A (es) | Derivados de carbamatos de alquil-heterociclos, su preparación y su aplicación en terapéutica | |
| WO2011045265A3 (en) | Spirocyclic derivatives as histone deacetylase inhibitors | |
| BR112018009223A8 (pt) | composição para camada de captura de buraco de elemento de conversão fotoelétrica orgânica |